Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients With Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study

TH Open
doi 10.1055/s-0039-1692202
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Georg Thieme Verlag KG

Related search

Optimal INR Level in Patients With Atrial Fibrillation With EHRA Type 2 Valvular Heart Disease Receiving Warfarin

Journal of Arrhythmia
Cardiovascular MedicineCardiology
2020English

Patients’ Priorities for Oral Anticoagulation Therapy in Non-Valvular Atrial Fibrillation: A Multi-Criteria Decision Analysis

American Journal of Cardiovascular Drugs
MedicineCardiovascular MedicinePharmacologyCardiology
2018English

International Variation in Use of Oral Anticoagulation Among Heart Failure Patients With Atrial Fibrillation

American Heart Journal
Cardiovascular MedicineCardiology
2012English

Analysis of the microRNA Signature in Left Atrium From Patients With Valvular Heart Disease Reveals Their Implications in Atrial Fibrillation

PLoS ONE
Multidisciplinary
2018English

The Antithrombotic Therapy of Atrial Fibrillation in Patients With Coronary Heart Disease

Russian Open Medical Journal
Medicine
2018English

Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients With ESRD: Verdict 2

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2016English

Atrial Fibrillation Onset Risk in Patients With Metabolic Syndrome: Prospective Study

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2014English

Under-Use of Warfarin for Patients With Non-Valvular Atrial Fibrillation in Japan

Internal Medicine
Internal MedicineMedicine
2004English

Anticoagulation in Patients With Atrial Fibrillation. Underuse of Warfarin Is Multifactorial.

BMJ
1993English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy